{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:21:38Z","timestamp":1781522498788,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Foundation of Fujian Province for Young Scientists","award":["2020J05304"],"award-info":[{"award-number":["2020J05304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The management of locally advanced prostate cancer (PCa) and oligometastatic prostate cancer (OMPCa) remains a clinical challenge. The heterogeneous nature of PCa prompts a need for precision treatment. This study aims to verify whether genomic biomarker-guided neoadjuvant therapy for locally advanced PCa and OMPCa can result in an improvement in the pathological responses and survival outcomes in a Chinese population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this open-label prospective phase II umbrella clinical trial, 40 patients will be enrolled. Next-generation sequencing data analysis of PCa tissues from the diagnostic needle biopsies will be performed. The genomically evaluable patients will be divided into 4 groups on the basis of genomic testing results, and receive 6 cycles of patient-tailored neoadjuvant systemic therapy targeted to alternative molecular pathways (including parmiparib, cisplatin, tislelizumab or docetaxel, respectively), and both in combination with rezvilutamide and goserelin microspheres. The primary endpoint is the rate of pathologic complete response. Secondary endpoints include rates of clinical complete response and pathological minimal residual disease (defined as residual tumor 5\u00a0mm or less), overall survival, progression-free survival and safety outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>SEGNO, to the best of our knowledge, is the first umbrella clinical trial designed to provide high-level evidence to support the implementation of genomic biomarker-guided neoadjuvant therapy for locally advanced PCa and OMPCa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Clinicaltrial.gov, NCT06387056.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13826-5","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:29:12Z","timestamp":1741638552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Haichao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"13826_CR1","doi-asserted-by":"crossref","unstructured":"Devos G, Devlies W, De Meerleer G, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021 Dec;18(12):739\u2013762.","DOI":"10.1038\/s41585-021-00514-9"},{"key":"13826_CR2","doi-asserted-by":"crossref","unstructured":"Zhu Y, Mo M, Wei Y, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18(5):282\u2013301.","DOI":"10.1038\/s41585-021-00442-8"},{"key":"13826_CR3","doi-asserted-by":"crossref","unstructured":"Chi C, Liu J, Fan L, et al. Efficacy of neoadjuvant docetaxel\u2009+\u2009cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. Ther Adv Med Oncol. 2022;30;14:17588359221128356.","DOI":"10.1177\/17588359221128356"},{"key":"13826_CR4","doi-asserted-by":"crossref","unstructured":"Pan J, Chi C, Qian H, et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Urol Oncol. 2019;37(12):991\u2013998.","DOI":"10.1016\/j.urolonc.2019.07.009"},{"key":"13826_CR5","doi-asserted-by":"crossref","unstructured":"Narita S, Nara T, Kanda S, et al. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clin Genitourin Cancer. 2019;17(1):e113-e122.","DOI":"10.1016\/j.clgc.2018.09.019"},{"key":"13826_CR6","doi-asserted-by":"crossref","unstructured":"Qian H, Chi C, Tricard T, et al. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy. J Urol. 2024;211(5):648\u2013655.","DOI":"10.1097\/JU.0000000000003876"},{"key":"13826_CR7","doi-asserted-by":"crossref","unstructured":"Chi C, Fan L, Dong B,et al. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. Clin Genitourin Cancer. 2021;19(4):e223-e234.","DOI":"10.1016\/j.clgc.2021.02.004"},{"key":"13826_CR8","unstructured":"Kent EC, Hussain MH. Neoadjuvant Therapy for Prostate Cancer: An Oncologist\u2019s Perspective. Rev Urol. 2003;5:3(3);S28-37."},{"key":"13826_CR9","doi-asserted-by":"crossref","unstructured":"Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008;22(2):243\u2009\u2212\u200958.","DOI":"10.1016\/j.beem.2008.01.003"},{"key":"13826_CR10","doi-asserted-by":"publisher","unstructured":"Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;16(11):645\u2013654. https:\/\/doi.org\/10.1038\/s41585-019-0237-8. Epub 2019 Oct 7.","DOI":"10.1038\/s41585-019-0237-8"},{"key":"13826_CR11","doi-asserted-by":"crossref","unstructured":"McKay RR, Ye H, Xie W, et al. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019;10:37(11);923\u2013931.","DOI":"10.1200\/JCO.18.01777"},{"key":"13826_CR12","doi-asserted-by":"crossref","unstructured":"Montgomery B, Tretiakova MS, Joshua AM, et al. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017;1:23(9):2169\u20132176.","DOI":"10.1158\/1078-0432.CCR-16-1357"},{"key":"13826_CR13","doi-asserted-by":"crossref","unstructured":"Graham LS, True LD, Gulati R, et al. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021;81(7):418\u2013426.","DOI":"10.1002\/pros.24118"},{"key":"13826_CR14","unstructured":"Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;20;32(33):3705-15."},{"key":"13826_CR15","doi-asserted-by":"crossref","unstructured":"Sowalsky AG, Ye H, Bhasin M, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018;15;78(16):4716\u20134730.","DOI":"10.1158\/0008-5472.CAN-18-0610"},{"key":"13826_CR16","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04812366"},{"key":"13826_CR17","doi-asserted-by":"crossref","unstructured":"Thalgott M, Horn T, Heck MM, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;5:7;20.","DOI":"10.1186\/1756-8722-7-20"},{"key":"13826_CR18","doi-asserted-by":"crossref","unstructured":"Lee LS, Sim AYL, Ong CW, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(4):741\u2013748.","DOI":"10.1038\/s41391-022-00496-8"},{"key":"13826_CR19","doi-asserted-by":"crossref","unstructured":"Waser NA, Quintana M, Schweikert B, et al. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectr. 2024;30;8(3):pkae021.","DOI":"10.1093\/jncics\/pkae021"},{"key":"13826_CR20","doi-asserted-by":"crossref","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164\u2009\u2212\u200972. doi: 10.1016\/S0140-6736(13)62422-8. Epub 2014 Feb 14. Erratum in: Lancet. 2019;9;393(10175):986.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"13826_CR21","doi-asserted-by":"crossref","unstructured":"Chen Y, Qin J, Wu Y, et al. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis. Int J Surg. 2023;1;109(9):2794\u20132807.","DOI":"10.1097\/JS9.0000000000000496"},{"key":"13826_CR22","doi-asserted-by":"crossref","unstructured":"Conforti F, Pala L, Bagnardi V, et al. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. JAMA Oncol. 2022;1;8(11):1668\u20131675.","DOI":"10.1001\/jamaoncol.2022.3755"},{"key":"13826_CR23","doi-asserted-by":"crossref","unstructured":"McKay RR, Montgomery B, Xie W, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018;21(3):364\u2013372.","DOI":"10.1038\/s41391-017-0009-6"},{"key":"13826_CR24","doi-asserted-by":"crossref","unstructured":"McKay RR, Berchuck J, Kwak L, et al. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021;205(6):1689\u20131697.","DOI":"10.1097\/JU.0000000000001632"},{"key":"13826_CR25","doi-asserted-by":"crossref","unstructured":"McKay RR, Xie W, Ye H, et al. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021;206(1):80\u201387.","DOI":"10.1097\/JU.0000000000001702"},{"key":"13826_CR26","doi-asserted-by":"crossref","unstructured":"Yanagisawa T, Rajwa P, Quhal F, et al. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. J Pers Med. 2023;7;13(4):641.","DOI":"10.3390\/jpm13040641"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13826-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:29:23Z","timestamp":1741638563000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13826-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13826"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13826-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the institutional ethics committee of the First Affiliated Hospital of Xiamen University. Written informed consent to participate will be obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}